** Shares of Alcidion Group slip as much as 5.7% to A$0.066
** Bell Potter cuts its price target for the healthcare tech co to A$0.07 from A$0.08, downgrades rating to "hold" from "sell"
** Brokerage also decreases its near-term revenue forecasts to better reflect the now-disclosed starting contracted revenue for FY25
** On Aug. 29, co revealed A$28.0 mln ($18.97 mln) of contracted and renewal revenue for FY25 as at August, a near A$6 mln stepdown from last year
** Brokerage now forecasts FY25 revenue for co of A$37 mln, a 20% drop from its previous forecast of A$46.1 mln
** "We are now more cautious considering the reduced starting revenue in FY25 and modest cash balance of A$11.8 mln with lumpy quarterly cashflows that are historically weaker in Q1-Q2" - brokerage
** Stock down ~7% YTD, as of last close
($1 = 1.4760 Australian dollars)
(Reporting by Echha Jain in Bengaluru)
((Echha.jain@thomsonreuters.com))
Comments